Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.59 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131459 | 1.00 | CYP3A4 (0.60) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL6369689 | 0.95 | KCNN4 (0.57) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL675338 | 0.92 | CYP3A4 (0.71) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL4466320 | 0.90 | CYP3A4 (0.56) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL14156831 | 0.89 | CYP3A4 (0.55) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL3368095 | 0.86 | CYP3A4 (0.52) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL27282170 | 0.86 | CYP19A1 (0.82) | CYP3A4CYP3A5CYP19A1KCNN4 | |
| SCHEMBL6369696 | 0.85 | CYP3A4 (0.47) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL6558548 | 0.84 | SLC2A1 (0.56) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A | |
| SCHEMBL4460626 | 0.84 | CYP3A4 (0.51) | CYP3A4CYP3A5CYP19A1KCNN4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773445-B1 | Diagnostic methods | GRIFFITH UNIVERSITY | 2023-10-03 | — | — | US | disclosed |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4110758-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | Tes Pharma S.r.l. (IT) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | CCNE2, CCNE1, CCNT1 | CYP3A4 32/4885CYP3A5 80/4885CYP19A1 95/4885 |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | CCNE2, CCNE1, CCNT1 | CYP3A4 32/4885CYP3A5 80/4885CYP19A1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.